Biosimilar medicines and patient registries – expectations, limitations, and opportunities
Introduction: Biology therapies in a various medical specializations and for a broad spectrum of indications were launched during last two decades. As a new in class the therapies were obliged to provide additional data re gar ding efficacy and safety after their real medical practice integration. P...
Main Authors: | Sutka R, Pec J, Pecova T |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2017-12-01
|
Series: | Acta Medica Martiniana |
Subjects: | |
Online Access: | https://doi.org/10.1515/acm-2017-0016 |
Similar Items
-
Centralised Biological Therapy Registry for Moderate to Severe Plaque Psoriasis – Overview and Methodology
by: Sutka R, et al.
Published: (2016-04-01) -
Biosimilars in India; current status and future perspectives
by: Bikash R Meher, et al.
Published: (2019-01-01) -
Biosimilars
by: Emel Bülbül Başkan
Published: (2022-04-01) -
The Coming of Age of Biosimilars: A Personal Perspective
by: Sarfaraz K. Niazi
Published: (2022-04-01) -
Portuguese Position Paper on the Use of Biosimilars in Psoriasis
by: Tiago Torres, et al.
Published: (2016-09-01)